Carlyle (NASDAQ: CG), has purchased a stake in Resonetics from private equity firm GTCR. The equity purchase values Resonetics at approximately $2.25 billion.
Resonetics is a micro-manufacturer of medical devices focused on fast-growing interventional and minimally-invasive applications in the MedTech industry. The firm concentrates on producing highly technical componentry for medical device applications in end markets including diabetes, neurovascular, ophthalmology, cardiology and more.
“Our business has advanced significantly over the past four years, as we’ve expanded our production capacity, grown our facility footprint and built greater scale,” said Tom Burns, CEO, Resonetics. “We have enjoyed the outstanding partnership with GTCR as we’ve built Resonetics and are excited to be partnering with GTCR and Carlyle in this next chapter as we continue to grow our business and enhance our product capabilities to better serve our customers.”
Kirkland & Ellis acted as legal advisor and Piper Sandler acted as financial advisor to Resonetics and GTCR. Debevoise & Plimpton acted as legal advisor and Barclays acted as financial advisor to Carlyle.